- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Drug discovery
Lilly's Alzheimer's drug trials show mixed results
August 24, 2012
Bloomberg News, J.K. WallEli Lilly and Co.’s experimental Alzheimer’s drug failed to meet its primary goals in two separate clinical trials.
However, when the results of both trials were combined, the drug appeared to have slowed the decline of cognition in some
patients.
MoreAlzheimer's quest puts Lilly to test
August 11, 2012
J.K. WallOdds are long that Eli Lilly and Co.'s leading Alzheimer's drug will show positive results when its Phase 3 trial results
are released within a few weeks, but even the smallest improvement in the cognitive impairment of test patients would be a
home run for Lilly.
MoreLilly stock slips after competitors halt Alzheimer's plans
August 7, 2012
IBJ Staff and Bloomberg NewsPfizer Inc., Johnson & Johnson and Elan Corp. are ending most plans to develop an Alzheimer’s drug after a second
trial failure. Eli Lilly is developing a similar treatment.
MorePotential Lilly antipsychotic falls short in study
July 11, 2012
Associated PressEli Lilly and Co. said a potential treatment for acute schizophrenia failed in a late-stage study that compared patients taking
the drug to those taking a placebo.
MoreIU research leads to new genetic test
June 4, 2012
J.K. WallIt took the identification of 19 different genes for researchers at the Indiana University School of Medicine to develop a test for a rare form of cancer. But their gene-hunting has paid off, as a Texas-based company announced Monday the test is available for doctors to use.
Good cholesterol may not lower heart risk, study suggests
May 17, 2012
Bloomberg NewsRaising good cholesterol, a goal pursued by Eli Lilly and Co. as the next milestone in cardiac care, may not cut heart-attack
risk, says a study that challenges the development of drugs that may someday generate billions of dollars in sales.
MoreRoche scraps hoped-for cholesterol blockbuster
May 7, 2012
Associated PressA second experimental cholesterol medicine in a once-promising class of drugs meant to replace blockbusters such as Lipitor
has failed in testing, casting doubt on whether any of the drugs will ever make it to pharmacies. Eli Lilly is developing
a similar drug.
MoreLilly: Forget Alzheimer's; think diabetes
May 7, 2012
J.K. WallFor more than a year, Eli Lilly and Co. has been viewed by investors as a laggard stock with one, slim shot at producing a
huge jackpot: its experimental Alzheimer’s drug. But now company leaders are trying to direct investor attention toward
the drugmaker’s diabetes portfolio.
MoreArrests made in $80M Lilly prescription drug heist
May 3, 2012
IBJ Staff and Associated Press, Bloomberg NewsAuthorities have arrested two Cuban brothers in the 2010 theft of about $80 million in Eli Lilly and Co. prescription drugs
from a Connecticut warehouse, a robbery described as one of the biggest pharmaceutical heists in history, the U.S. attorney's
office said Thursday.
MoreLilly letting U.S. researchers test failed compounds for new uses
May 3, 2012
Bloomberg NewsMore than 20 compounds that Eli Lilly and Co., Pfizer Inc. and AstraZeneca Plc failed to turn into drugs will be tested by
U.S.-sponsored scientists in a $20 million program to see if they’ll work against ailments they weren’t aimed
at previously.
MoreEndocyte could get $1B from Merck development deal
April 16, 2012
Associated PressEndocyte Inc. stock more than doubled in premarket trading after the company entered into an agreement to develop its ovarian
cancer treatment with pharmaceutical giant Merck & Co.
MoreNew Lilly drug has small sales potential
April 9, 2012
J.K. WallEli Lilly and Co.’s newest drug is a boon for Alzheimer’s research but is likely to bring the Indianapolis drugmaker
less than $100 million in annual sales—at least initially, according to one of the few analysts to make a forecast.
MoreEndocyte pulls trigger on European drug submission
March 13, 2012
J.K. WallEndocyte Inc. will submit its ovarian cancer drug EC145 for European market approval in the third quarter of this year after
the European Commission granted it orphan drug status.
MoreFDA removes hurdle in Endocyte's path to drug approval
March 5, 2012
J.K. WallEndocyte Inc. can start enrolling patients again in a clinical trial of its experimental cancer drug, the company announced
Monday, clearing away a hurdle to getting the drug approved in Europe.
MoreLechleiter bets history will repeat for Lilly
January 16, 2012
J.K. WallEli Lilly and Co. CEO John Lechleiter keeps pouring more money into research and development, even as analysts note the payoff
of such spending has dropped off 70 percent in the last decade.
MoreEndocyte stays course despite being battered by investors
December 31, 2011
J.K. WallAfter spending most of 2011 as a Wall Street darling, the year ended ugly for Endocyte Inc. But CEO Ron Ellis thinks the West
Lafayette-based drug developer is in better position than ever.
MoreLilly losing dominance in diabetes treatment
December 31, 2011
J.K. WallEli Lilly and Co., after more than a decade of setbacks, is counting on diabetes to help it survive a string of patent losses
on other products that have begun to sap the drugmaker's sales.
MoreEndocyte shares plunge on clinical trial results
December 13, 2011
J.K. WallShares of Endocyte Inc. plummeted more than 60 percent Tuesday morning after clinical trial results showed the company’s
experimental ovarian cancer drug led to shorter survival times than treatment with a standard cancer drug.
MoreLilly shares rise on possibility for Alzheimer’s drug
December 7, 2011
Bloomberg NewsEli Lilly and Co. stock rose to a one-month high Tuesday after an analyst said the possible success of the company’s
experimental Alzheimer’s drug could double the share price.
MorePotential Lilly drug doubles good cholesterol
November 15, 2011
Bloomberg NewsEli Lilly and Co.’s experimental drug doubled levels of good cholesterol in a study, setting up a race with Merck &
Co. and Roche Holding AG to develop a new class of medicines to lower heart risk.
MorePotential Effient rival shows promise in study
November 14, 2011
Bloomberg NewsA study showing Johnson & Johnson and Bayer AG’s blood-thinner Xarelto succeeded where rival drugs failed could
give the companies entry to a $1 billion-plus market where Eli Lilly already competes.
MoreLilly, Amylin agree to end diabetes partnership
November 8, 2011
Bloomberg News, Associated PressAmylin Pharmaceuticals Inc. and Eli Lilly and Co. have agreed to end a decade-long diabetes partnership to resolve litigation.
Amylin will make an upfront payment of $250 million to Lilly and future revenue-sharing payments of $1.2 billion plus interest.
MoreLilly fights view that fate hinges on Alzheimer's drug
October 29, 2011
Greg AndrewsAnalysts have eyes on trial data for drug that could be a game-changer for the company.
MoreLilly wins European approval for new use of Alimta
October 28, 2011
J.K. WallIndianapolis-based drugmaker can now market lung cancer drug as a continuation maintenance therapy, potentially boosting sales
after recent loss of patent on bestseller Zyprexa.
MoreQ&A
October 17, 2011
J.K. WallSherry Keramidas, who earned her doctorate in neuroscience and physiological psychology from Purdue University,
is executive director of the Maryland-based Regulatory Affairs Professionals Society, which is holding its annual conference
Oct. 22-26 at the Indiana Convention Center.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
liek the rest of America
These quaint,obsessed musings by the stalkers are certainly entertaining, but I'm trying to figure out what, if anything, all the yelping below has to do with Zak Brown.
It's evident that Moffett was pushing the right buttons and corporate America is now trying to squash him. He just wanted to withdraw the free pilot services provided to the company by the pilots to try and put some pressure on a company that has not been interested in negotiating a contract in over 5 years. The company does not provide a contract because not having one has saved them a bundle of money. Shame on any Republic pilots not standing behind their union leader just because things are getting tough, can you not see such strategic moves by the company as putting the last union president in a corporate position and into THEIR pocket. Do you really believe the last union president is so appalled at the attempts by Moffett, do you not remember his oppositions to the company? We stood behind him. It has been proven over and over again for thousands of years without fail, a man cannot serve two masters. Anyone that believes people vote contrary to their paycheck and livelihood deserve to be taken advantage of, the recent statements by the former union president are laughable as he denounces the current union president from his new corporate position. Have you ever seen a drafted sports player score points for his previous team, it cannot be done, he is not on the pilots side anymore, he gets his money a different way now than you and I do, and he should not be allowed to remain on the seniority list. A drafted player brings strength, credibility, tactical knowledge, and a strategic advantage to his NEW team, he would not be drafted or paid were it otherwise. We are all forced to choose only one side to play for and support, not doing so has many references in life such as insider trading and shaving points, all illegal for good reason. This basic fact is why corporate moguls, scientist, and engineers all sign non-discloser agreements and non-compete clauses, as protection in case they are lured into switching sides as our former union president has done. No NFL coach ever drafted a player so that both teams could benefit and better understand each other, they are recruited to win the game against that former team, period. Likewise the company does not recruit the former union president by accident or mutual understanding, its strategy. Don't confuse playing the game with good sportsman-like conduct in support of common business and prosperity goals, with the requirement to only play for one side. Good men we all love and favor fall subject to this manipulation, often without their knowledge, and it is not a betrayal of their friendship to oppose them when they switch sides. If we did not love and trust them, they would not have been chosen and lured to the other side in the first place. The deception by the drafted player is not made at a conscious level, it's just human nature and it's all about money and power which corrupts our ability to be objective and loyal to two masters. This is why our court system created the defense attorney, and why our military created counter intelligence. Its strategy and its propaganda, and it works, and that's why the "powers to be" manipulate the chess pieces by sometimes changing their colors. Some players know they are being manipulated when their color is changed, but it brings them more money and power so they do not care. The rest have good intentions but do not even realize they are being manipulated. This tactic is also known by another name, Divide and Conquer. In battle sending an imperfect message with an imperfect team is obviously not ideal, but it's still being sent by YOUR team, your union leader, a leader that has common goals and common rewards with you, they are the best, because we have elected them to do a job for us. If you are not backing Moffett but believing the spin by those that have recently switched sides, you are taking food out of your own mouth. Showing unity and backing an imperfect situation still results in taking just as much ground, it's about unity and bargaining power. It's not necessary to wait around for that perfect attack because it will never come, the company will spin and attempt to destroy anyone that gets in their way. Ultimately it's not about any specific attack anyway, ASAP or whatever it makes no difference, it is and always has been only about power. If this company cared about safety it would not build pairings with 8 hour overnights, come on, are you that naive? Besides, do you really think Hoffa cares, no, he got a call from corporate America and was squeezed into denouncing Moffett. If he didn't they would spin the safety card against him and the Teamsters National with implication for truckers, future contracts, insurance rates etc...saying something like the Teamsters use safety as a bargaining chip, blah blah blah... Do you really think any pilot is going to do something unsafe for the contract, absolutely not, the only ones threatening safety here is the company with reduced rest, fatigue, and poverty. Do you not find it odd that Hoffa and the Teamsters are opposing a Teamster president publicly? Would the Teamsters National not normally support and work with one of their own? Why did they not sit down and help him strategize, correct any mistakes, and charge ahead? Would the Teamsters National not normally support and leverage a contract for all those pilots that have been paying Teamster dues, isn't that why we have all been paying Teamster dues in the first place? I sure haven't been paying dues so that the Teamsters National could come along and write this kind of an article undercutting our union leader and our unity. Whose side is the Teamsters National really on, it's obviously not the Republic pilots side.
No matter what Moffatt does the company is going to spin it like he is the terrorist and brainwash people like you into believing it, wake up, back your players that are trying to change things for you and your livelihood. Where has Hoffa been for the last 6 years, except collecting our dues. Seriously, do you really think an FO going for upgrade, signed off by a checkairman ready for the upgrade, who then fails, is not even capable of returning as a First Officer.
whoa!